Skip to main content

Table 2 Clinician-Reported Participant Characteristics

From: The content validity of the PSS in patients with plaque psoriasis

 

Total Sample (N = 20)

Time Since Psoriasis Diagnosis, years

 Mean ± SD

17.9 ± 9.9

 Median (IQR)

19.6 (11.1–24.1)

 Range (Min – Max)

(0.2–38.6)

Time on Systemic Treatment, years

 Mean ± SD

4.4 ± 4.8

 Median (IQR)

2.3 (1.4–7.0)

 Range (Min – Max)

(0.1–20.0)

Comorbidities, n (%)

 Anxiety

2 (10%)

 Depression

2 (10%)

 Psoriatic Arthritis

4 (20%)

 Othera

12 (60%)

 No other health conditions

8 (40%)

Current treatmentsb, n (%)

 Secukinumab

1 (5%)

 Etanercept

3 (15%)

 Folic Acid

1 (5%)

 Adalimumab

4 (20%)

 Ixekizumab

4 (20%)

 Methotrexate

1 (5%)

 Ustekinumab

5 (25%)

 Ultraviolet B (shortwave) Waves (UVB)

2 (10%)

 Other

1 (5%)

  1. aNot mutually exclusive; other comorbidities included: atrial fibrillation, diabetes [6], hyperlipidemia [2], hypertension [5], obesity [2], restless legs, hypothyroidism, post-menopausal, peripheral edema.
  2. bNot mutually exclusive